Symbols / EVO Stock $2.92 -2.02% Evotec SE

Healthcare • Drug Manufacturers - Specialty & Generic • Germany • NMS
EVO (Stock) Chart
O: — H: — L: — C: — V: —
SMA 20: — SMA 50: — SMA 200: —
Stock Fundamentals
Scroll to Statements
Index EQUITY
Sector Healthcare
Industry Drug Manufacturers - Specialty & Generic
CEO Dr. Christian Wojczewski Ph.D.
Exch · Country NMS · Germany
Market Cap 1.04B
Enterprise Value 500.99M
Income -103.52M
Sales 788.37M
FCF (ttm) -55.54M
Book/sh 2.68
Cash/sh 2.68
Employees 4,467
Insider 10d —
IPO Feb 05, 2004
Div forward ($/yr)
Div TTM ($/yr)
Dividend Yield
Ex-Div Date
5Y Avg Yield
Yield vs 5Y Avg
Payout 0.00%
P/E —
Forward P/E -15.37
PEG 1.42
P/S 1.32
P/B 1.09
P/C —
EV/EBITDA 57.30
EV/Sales 0.64
Quick Ratio 1.84
Current Ratio 2.07
Debt/Eq 55.02
LT Debt/Eq —
EPS (ttm) -0.34
EPS next Y -0.19
EPS Growth —
Revenue Growth 14.50%
EPS Gr Q/Q —
Rev Gr Q/Q —
Earnings (next) 2026-05-06
Earnings (prior) 2026-04-08
ROA -2.28%
ROE -11.72%
ROIC —
Gross Margin 14.49%
Oper. Margin 9.16%
Profit Margin -13.13%
Shs Outstand 355.19M
Shs Float 133.73M
Insider Own 0.00%
Instit Own 2.63%
Short Float 0.12%
Short Ratio 3.76
Short Interest 409.47K
52W High 4.80
vs 52W High -39.17%
52W Low 2.31
vs 52W Low 26.40%
Beta 1.24
Impl. Vol. —
Rel Volume 0.07
Avg Volume 158.18K
Volume 11.86K
Target (mean) $5.21
Tgt Median $5.45
Tgt Low $3.00
Tgt High $6.95
# Analysts 4
Recom Buy
Prev Close $2.98
Price $2.92
Change -2.02%
About

Evotec SE operates as a drug discovery and development company in the United States, Germany, France, the United Kingdom, Switzerland, and internationally. It operates in two segments, Shared R&D and Just – Evotec Biologics. The company is developing pharmaceutical products in various therapeutic areas, such as oncology, autoimmune, cancer, diabetes, heart failure, immunology, pain and inflammation, infectious, kidney, liver, respiratory, fibrotic and metabolic diseases, and rare diseases. It is also developingcentral nervous system (CNS) and cardiometabolic diseases; and animal and women health. The company has collaboration agreements with Mass General Brigham and Joslin Diabetes Center focusing on cardiometabolic diseases; BMS antiviral; Novo Nordisk cell therapy; University of Oxford; German Cancer Research Center; University Hospital in Hamburg; University of Toronto, Harvard, and Yale; Johns Hopkins University; Ospedale San Raffaele (OSR); and National University of Singapore. In addition, it has a partnership with LAB282, LAB150, beLAB2122, beLAB1407, LAB eN², Danube Labs, VC Amplitude Ventures, LaB eN2, and 65LAB. Further, the company serves pharma and biotechnology companies, academic institutions, patient advocacy groups, and venture capital. The company was formerly known as Evotec AG and changed its name to Evotec SE in April 2019. Evotec SE was incorporated in 1993 and is headquartered in Hamburg, Germany.

Valuation Models

Price estimates from analyst targets and simple models.

1. Analyst consensus
$5.21
Mean price target
2. Current target
$2.92
Latest analyst target
3. DCF / Fair value
$-2.81
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$2.92
Low
$3.00
High
$6.95
Mean
$5.21

Latest analyst rating changes

Date Action Analyst Rating Change Price Target
2025-08-14 main HC Wainwright & Co. Buy → Buy $7
2024-11-07 reit HC Wainwright & Co. Buy → Buy $8
2024-08-15 main HC Wainwright & Co. Buy → Buy $8
2024-05-23 reit HC Wainwright & Co. Buy → Buy $11
2024-04-25 main HC Wainwright & Co. Buy → Buy $11
2023-08-31 main HC Wainwright & Co. Buy → Buy $14
2023-07-12 reit HC Wainwright & Co. Buy → Buy $12
2023-06-23 up Morgan Stanley Equal-Weight → Overweight $16
2023-06-16 down B of A Securities Buy → Neutral $13
2023-06-08 up Citigroup Neutral → Buy —
2023-04-04 up Morgan Stanley Underweight → Equal-Weight —
2023-03-29 reit HC Wainwright & Co. — → Buy $12
2023-01-27 reit HC Wainwright & Co. — → Buy $12
2022-12-09 init HC Wainwright & Co. — → Buy $12
2022-11-16 down Deutsche Bank Buy → Hold —
2022-08-10 down Morgan Stanley Overweight → Underweight $16
2021-11-29 init Cowen & Co. — → Outperform —
News
RSS: Latest EVO news
Insider Transactions

No recent insider transactions.

Financials
Statement View
Amounts in millions (2 decimals, no suffix) • EPS per share (2 decimals) • Trend = period evolution • YoY Growth = previous period %
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Total Revenue
788.37
-1.08%
796.97
+1.99%
781.43
+3.99%
751.45
Operating Revenue
788.37
-1.08%
796.97
+1.99%
781.43
+3.99%
751.45
Cost Of Revenue
674.15
-1.16%
682.09
+12.49%
606.38
+5.02%
577.38
Reconciled Cost Of Revenue
674.15
-1.16%
682.09
+12.49%
606.38
+5.02%
577.38
Gross Profit
114.22
-0.57%
114.88
-34.37%
175.05
+0.57%
174.06
Operating Expense
170.04
-12.26%
193.80
-3.91%
201.68
+31.63%
153.22
Research And Development
37.51
-26.25%
50.86
-25.79%
68.53
-10.59%
76.64
Selling General And Administration
175.97
-6.50%
188.20
+10.96%
169.61
+8.59%
156.19
Selling And Marketing Expense
17.38
-0.58%
17.48
+3.61%
16.87
+25.04%
13.49
General And Administrative Expense
158.59
-7.10%
170.72
+11.77%
152.74
+7.04%
142.70
Other Gand A
158.59
-7.10%
170.72
+11.77%
152.74
+7.04%
142.70
Other Operating Expenses
-1.83
+81.61%
-9.93
-1456.90%
-0.64
+98.65%
-47.30
Total Expenses
844.19
-3.62%
875.89
+8.39%
808.05
+10.60%
730.60
Operating Income
-55.82
+29.27%
-78.92
-196.38%
-26.63
-227.71%
20.85
Total Operating Income As Reported
-56.22
+60.56%
-142.52
-200.00%
-47.51
-327.85%
20.85
EBITDA
27.15
+133.66%
-80.66
-434.34%
24.12
+141.88%
-57.61
Normalized EBITDA
28.23
+31.56%
21.46
-60.37%
54.15
-50.61%
109.64
Reconciled Depreciation
99.48
-2.11%
101.62
+9.29%
92.98
+11.76%
83.20
EBIT
-72.32
+60.32%
-182.28
-164.73%
-68.85
+51.10%
-140.81
Total Unusual Items
-1.08
+98.95%
-102.12
-240.13%
-30.02
+82.05%
-167.25
Total Unusual Items Excluding Goodwill
-1.08
+98.95%
-102.12
-240.13%
-30.02
+82.05%
-167.25
Special Income Charges
-0.40
+99.37%
-63.60
-204.62%
-20.88
-525.43%
4.91
Other Special Charges
1.68
-80.63%
8.67
-45.34%
15.87
—
Impairment Of Capital Assets
0.00
0.00
-100.00%
5.01
0.00
Restructuring And Mergern Acquisition
0.63
-98.85%
54.93
0.00
+100.00%
-4.91
Write Off
—
—
—
-0.87
Net Income
-103.52
+47.21%
-196.08
-133.67%
-83.91
+52.23%
-175.66
Pretax Income
-86.77
+55.27%
-193.98
-140.69%
-80.59
+47.65%
-153.96
Net Non Operating Interest Income Expense
-10.02
-8.14%
-9.26
-274.15%
-2.48
+48.57%
-4.81
Interest Expense Non Operating
14.44
+23.45%
11.70
-0.34%
11.74
-10.73%
13.15
Net Interest Income
-10.02
-8.14%
-9.26
-274.15%
-2.48
+48.57%
-4.81
Interest Expense
14.44
+23.45%
11.70
-0.34%
11.74
-10.73%
13.15
Interest Income Non Operating
4.42
+81.68%
2.44
-73.71%
9.26
+11.12%
8.34
Interest Income
4.42
+81.68%
2.44
-73.71%
9.26
+11.12%
8.34
Other Income Expense
-20.93
+80.22%
-105.79
-105.47%
-51.49
+69.71%
-169.99
Other Non Operating Income Expenses
-18.77
-3051.10%
0.64
+189.08%
-0.71
-105.78%
12.36
Gain On Sale Of Security
-0.68
+98.24%
-38.51
-321.23%
-9.14
+94.69%
-172.16
Gain On Sale Of Business
1.91
—
—
—
Tax Provision
16.75
+696.91%
2.10
-36.69%
3.32
-84.70%
21.70
Tax Rate For Calcs
0.00
+0.00%
0.00
+0.00%
0.00
+0.00%
0.00
Tax Effect Of Unusual Items
-0.16
+98.95%
-15.32
-240.13%
-4.50
+82.05%
-25.09
Net Income Including Noncontrolling Interests
-103.52
+47.21%
-196.08
-133.67%
-83.91
+52.23%
-175.66
Net Income From Continuing Operation Net Minority Interest
-103.52
+47.21%
-196.08
-133.67%
-83.91
+52.23%
-175.66
Net Income From Continuing And Discontinued Operation
-103.52
+47.21%
-196.08
-133.67%
-83.91
+52.23%
-175.66
Net Income Continuous Operations
-103.52
+47.21%
-196.08
-133.67%
-83.91
+52.23%
-175.66
Minority Interests
—
—
—
0.00
Normalized Income
-102.60
+6.11%
-109.28
-87.14%
-58.39
-74.35%
-33.49
Net Income Common Stockholders
-103.52
+47.21%
-196.08
-133.67%
-83.91
+52.23%
-175.66
Diluted EPS
-0.29
+47.75%
-0.56
-136.17%
-0.23
+52.53%
-0.49
Basic EPS
-0.29
+47.75%
-0.56
-136.17%
-0.23
+52.53%
-0.49
Basic Average Shares
355.16
+0.16%
354.59
+0.21%
353.83
+0.14%
353.35
Diluted Average Shares
355.16
+0.16%
354.59
+0.21%
353.83
+0.14%
353.35
Diluted NI Availto Com Stockholders
-103.52
+47.21%
-196.08
-133.67%
-83.91
+52.23%
-175.66
Earnings From Equity Interest
-1.08
+74.84%
-4.31
+79.22%
-20.75
-37.45%
-15.10
Other Taxes
-41.61
-17.80%
-35.33
+1.39%
-35.82
-10.84%
-32.32
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Total Assets
1,713.94
-10.38%
1,912.50
-15.09%
2,252.47
-0.21%
2,257.25
Current Assets
762.95
+11.87%
681.96
-24.49%
903.16
-15.88%
1,073.67
Cash Cash Equivalents And Short Term Investments
463.01
+25.93%
367.68
-39.14%
604.11
-14.59%
707.31
Cash And Cash Equivalents
401.79
+36.92%
293.46
-42.56%
510.91
+27.51%
400.70
Cash Equivalents
234.06
+6470.92%
3.56
-98.70%
273.35
+48.93%
183.54
Cash Financial
167.73
-42.14%
289.89
+22.03%
237.56
+9.40%
217.16
Other Short Term Investments
61.23
-17.50%
74.22
-20.37%
93.20
-69.60%
306.61
Receivables
213.51
-2.23%
218.38
-1.59%
221.90
-19.54%
275.77
Accounts Receivable
135.96
+16.89%
116.32
+18.22%
98.40
-42.73%
171.80
Gross Accounts Receivable
150.05
+17.72%
127.46
+21.57%
104.85
-40.09%
175.02
Allowance For Doubtful Accounts Receivable
-14.09
-26.43%
-11.14
-72.65%
-6.45
-100.22%
-3.22
Other Receivables
28.30
-38.53%
46.03
+84.14%
25.00
-18.08%
30.52
Taxes Receivable
49.25
-12.09%
56.03
-43.12%
98.50
+34.10%
73.46
Inventory
29.32
-5.80%
31.12
+0.75%
30.89
+3.57%
29.82
Raw Materials
26.98
-8.39%
29.45
+13.72%
25.90
-7.22%
27.92
Work In Process
2.33
+39.95%
1.67
-66.59%
4.99
+161.48%
1.91
Prepaid Assets
18.97
-14.70%
22.24
+20.90%
18.39
+8.54%
16.95
Restricted Cash
33.59
+0.53%
33.41
+182.71%
11.82
-18.25%
14.46
Assets Held For Sale Current
3.83
—
—
—
Hedging Assets Current
—
4.29
-66.38%
12.76
+55.31%
8.21
Other Current Assets
0.71
-92.24%
9.13
-39.56%
15.11
-28.55%
21.14
Total Non Current Assets
951.00
-22.72%
1,230.54
-8.80%
1,349.31
+14.00%
1,183.58
Net PPE
554.62
-32.69%
823.94
+2.15%
806.56
+24.05%
650.20
Gross PPE
1,074.17
-17.47%
1,301.59
+12.51%
1,156.87
+25.64%
920.81
Accumulated Depreciation
-519.54
-8.77%
-477.65
-36.35%
-350.31
-29.45%
-270.61
Properties
0.00
0.00
0.00
0.00
Buildings And Improvements
313.88
-2.84%
323.07
+17.76%
274.33
+14.15%
240.33
Machinery Furniture Equipment
482.80
-3.31%
499.34
+23.97%
402.79
+19.64%
336.68
Construction In Progress
25.63
-89.84%
252.25
+11.79%
225.65
+93.88%
116.38
Other Properties
15.31
+255.81%
4.30
+1.25%
4.25
-9.32%
4.69
Leases
236.55
+6.25%
222.62
-10.90%
249.85
+12.18%
222.73
Goodwill And Other Intangible Assets
303.94
-1.73%
309.30
+6.25%
291.09
-2.53%
298.64
Goodwill
272.37
-3.71%
282.85
+2.62%
275.63
+0.30%
274.82
Other Intangible Assets
31.57
+19.40%
26.44
+71.09%
15.45
-35.12%
23.82
Investments And Advances
52.63
+24.86%
42.15
-70.34%
142.09
-5.48%
150.33
Long Term Equity Investment
4.63
+116.51%
2.14
-30.38%
3.07
-80.86%
16.04
Other Investments
—
40.01
-71.22%
139.02
+6.09%
131.04
Non Current Accounts Receivable
36.35
+5.80%
34.36
-63.60%
94.39
+34.29%
70.29
Non Current Deferred Assets
2.95
-82.99%
17.33
+20.96%
14.33
+38.76%
10.33
Non Current Deferred Taxes Assets
2.95
-82.99%
17.33
+20.96%
14.33
+38.76%
10.33
Other Non Current Assets
0.51
-85.34%
3.46
+313.48%
0.84
-77.86%
3.79
Total Liabilities Net Minority Interest
900.24
-6.22%
959.98
-15.24%
1,132.56
+5.84%
1,070.06
Current Liabilities
368.07
+6.82%
344.58
-25.83%
464.57
+37.57%
337.71
Payables And Accrued Expenses
81.03
-18.78%
99.77
-30.08%
142.68
+31.97%
108.11
Payables
81.03
-18.78%
99.77
-30.08%
142.68
+31.97%
108.11
Accounts Payable
64.76
-24.51%
85.79
-36.13%
134.32
+38.08%
97.28
Pensionand Other Post Retirement Benefit Plans Current
5.64
-29.46%
8.00
+80.70%
4.43
-0.96%
4.47
Total Tax Payable
16.27
+16.43%
13.97
+67.19%
8.36
-22.88%
10.84
Income Tax Payable
10.58
+24.20%
8.52
+53.05%
5.57
-38.08%
8.99
Current Debt And Capital Lease Obligation
103.68
+104.12%
50.80
-65.93%
149.10
+810.18%
16.38
Current Debt
81.50
+60.45%
50.80
-65.93%
149.10
+9482.01%
1.56
Other Current Borrowings
81.50
—
129.97
+8252.89%
1.56
Current Capital Lease Obligation
22.18
—
19.11
+28.94%
14.82
Current Deferred Liabilities
108.07
-1.59%
109.81
+1.82%
107.86
-21.08%
136.67
Current Deferred Revenue
108.07
-1.59%
109.81
+1.82%
107.86
-21.08%
136.67
Other Current Liabilities
11.10
-20.62%
13.99
-8.89%
15.35
-13.06%
17.66
Total Non Current Liabilities Net Minority Interest
532.17
-13.52%
615.39
-7.87%
667.99
-8.79%
732.36
Long Term Debt And Capital Lease Obligation
344.01
-12.41%
392.74
-17.68%
477.11
-2.69%
490.29
Long Term Debt
344.01
-12.41%
392.74
-17.68%
477.11
+45.33%
328.30
Long Term Capital Lease Obligation
—
—
170.03
+4.95%
162.00
Long Term Provisions
18.04
-7.91%
19.59
+21.93%
16.06
-2.22%
16.43
Non Current Deferred Liabilities
168.41
-16.53%
201.75
+16.33%
173.42
-22.81%
224.66
Non Current Deferred Revenue
153.67
-17.92%
187.24
+20.57%
155.29
-24.67%
206.14
Non Current Deferred Taxes Liabilities
14.73
+1.51%
14.52
-19.96%
18.14
-2.09%
18.52
Other Non Current Liabilities
1.72
+30.72%
1.31
-5.48%
1.39
+42.07%
0.98
Stockholders Equity
813.70
-14.57%
952.52
-14.95%
1,119.91
-5.67%
1,187.18
Common Stock Equity
813.70
-14.57%
952.52
-14.95%
1,119.91
-5.67%
1,187.18
Capital Stock
177.78
+0.13%
177.55
+0.21%
177.19
+0.13%
176.95
Common Stock
177.78
+0.13%
177.55
+0.21%
177.19
+0.13%
176.95
Share Issued
177.78
+0.03%
177.72
+0.16%
177.44
+0.13%
177.20
Ordinary Shares Number
177.46
-0.05%
177.55
+0.21%
177.19
+0.13%
176.95
Treasury Shares Number
0.32
+90.85%
0.17
-33.01%
0.25
+0.00%
0.25
Additional Paid In Capital
1,458.47
+0.26%
1,454.69
+0.35%
1,449.65
+0.67%
1,440.01
Retained Earnings
-775.89
-15.40%
-672.37
-41.17%
-476.29
-21.39%
-392.38
Gains Losses Not Affecting Retained Earnings
-45.11
-513.94%
-7.35
+76.02%
-30.64
+18.07%
-37.40
Treasury Stock
1.55
0.00
—
—
Minority Interest
—
—
—
0.00
Other Equity Adjustments
-45.11
-513.94%
-7.35
+76.02%
-30.64
+18.07%
-37.40
Total Equity Gross Minority Interest
813.70
-14.57%
952.52
-14.95%
1,119.91
-5.67%
1,187.18
Total Capitalization
1,157.71
-13.94%
1,345.27
-15.76%
1,597.02
+5.38%
1,515.48
Working Capital
394.87
+17.04%
337.38
-23.08%
438.59
-40.41%
735.97
Invested Capital
1,239.21
-11.24%
1,396.06
-20.05%
1,746.12
+15.10%
1,517.04
Total Debt
447.69
+0.94%
443.54
-29.17%
626.21
+23.59%
506.67
Net Debt
23.72
-84.19%
150.08
+30.17%
115.30
—
Capital Lease Obligations
22.18
—
189.14
+6.97%
176.82
Net Tangible Assets
509.77
-20.75%
643.23
-22.39%
828.82
-6.72%
888.55
Tangible Book Value
509.77
-20.75%
643.23
-22.39%
828.82
-6.72%
888.55
Available For Sale Securities
48.00
+19.97%
40.01
+1066.59%
3.43
+5.64%
3.25
Current Provisions
58.54
-5.91%
62.22
+37.76%
45.16
-16.99%
54.41
Duefrom Related Parties Current
—
—
—
3.15
Investmentin Financial Assets
48.00
+19.97%
40.01
+1066.59%
3.43
+5.64%
3.25
Line Of Credit
—
—
—
1.56
Other Equity Interest
—
0.00
+0.00%
0.00
—
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Operating Cash Flow
-9.18
-150.38%
18.22
-50.00%
36.44
-82.29%
205.81
Cash Flow From Continuing Operating Activities
-9.18
-150.40%
18.22
-50.00%
36.44
-82.30%
205.81
Net Income From Continuing Operations
-103.52
+47.21%
-196.08
-133.67%
-83.91
+52.23%
-175.66
Depreciation Amortization Depletion
99.48
-2.11%
101.62
+9.29%
92.98
+11.76%
83.20
Depreciation
—
—
92.98
+27.93%
72.68
Amortization Cash Flow
—
—
—
8.98
Depreciation And Amortization
99.48
-2.11%
101.62
+9.29%
92.98
+11.76%
83.20
Amortization Of Intangibles
—
—
—
8.98
Other Non Cash Items
28.99
-12.06%
32.97
+1295.09%
2.36
+131.98%
-7.39
Stock Based Compensation
3.78
-24.97%
5.04
-47.72%
9.63
-2.91%
9.92
Asset Impairment Charge
0.80
-93.46%
12.20
+143.36%
5.01
0.00
Deferred Tax
16.75
+696.91%
2.10
-36.69%
3.32
-84.70%
21.70
Deferred Income Tax
16.75
+696.91%
2.10
-36.69%
3.32
-84.70%
21.70
Operating Gains Losses
-7.29
-156.25%
12.96
-37.55%
20.75
+37.45%
15.10
Gain Loss On Investment Securities
-12.12
—
—
—
Unrealized Gain Loss On Investment Securities
-2.14
-105.41%
39.55
+332.53%
9.14
-94.69%
172.16
Net Foreign Currency Exchange Gain Loss
—
—
—
-9.42
Gain Loss On Sale Of PPE
—
—
—
0.18
Change In Working Capital
-60.80
+10.85%
-68.21
-585.91%
-9.94
-109.44%
105.28
Change In Receivables
-28.73
+29.49%
-40.74
-155.61%
73.26
+236.48%
-53.68
Changes In Account Receivables
-28.73
+29.49%
-40.74
-155.61%
73.26
+290.64%
-38.43
Change In Inventory
-9.56
-255.86%
-2.69
-67.52%
-1.60
+63.63%
-4.41
Change In Payables And Accrued Expense
-7.30
+85.32%
-49.75
-361.51%
19.02
-64.73%
53.94
Change In Payable
-7.30
+85.32%
-49.75
-361.51%
19.02
-64.73%
53.94
Change In Account Payable
-7.30
+85.32%
-49.75
-361.51%
19.02
-22.51%
24.55
Change In Other Working Capital
-15.21
-160.90%
24.97
+124.82%
-100.62
-151.48%
195.44
Change In Other Current Assets
—
—
—
-81.33
Change In Other Current Liabilities
—
—
—
9.29
Investing Cash Flow
171.59
+341.04%
-71.19
-435.60%
-13.29
+96.78%
-412.80
Cash Flow From Continuing Investing Activities
171.59
+341.04%
-71.19
-435.60%
-13.29
+96.78%
-412.80
Net PPE Purchase And Sale
-72.33
+37.36%
-115.47
+45.74%
-212.79
-17.33%
-181.35
Purchase Of PPE
-72.54
+38.25%
-117.47
+44.93%
-213.32
-17.63%
-181.35
Sale Of PPE
0.21
-89.30%
2.00
+277.36%
0.53
0.00
Capital Expenditure
-82.62
+37.52%
-132.24
+38.78%
-216.00
-19.10%
-181.35
Net Investment Purchase And Sale
31.97
+409.13%
6.28
-97.04%
211.97
+240.70%
-150.65
Purchase Of Investment
0.00
+100.00%
-29.39
+39.27%
-48.39
+86.40%
-355.82
Sale Of Investment
31.97
-10.37%
35.67
-86.30%
260.36
+26.90%
205.17
Net Business Purchase And Sale
216.86
+406.88%
42.78
+312.22%
-20.16
+75.95%
-83.82
Purchase Of Business
-13.97
+47.46%
-26.59
-12.44%
-23.64
+71.79%
-83.82
Gain Loss On Sale Of Business
3.75
-56.64%
8.65
0.00
0.00
Net Intangibles Purchase And Sale
-10.08
+31.75%
-14.77
-451.70%
-2.68
0.00
Purchase Of Intangibles
-10.08
+31.75%
-14.77
-451.70%
-2.68
0.00
Net Other Investing Changes
0.00
-99.98%
4.34
—
-4.13
Financing Cash Flow
-37.63
+76.69%
-161.42
-324.31%
71.96
+223.76%
-58.15
Cash Flow From Continuing Financing Activities
-37.63
+76.69%
-161.42
-324.31%
71.96
+223.76%
-58.15
Net Issuance Payments Of Debt
-29.42
+80.66%
-152.07
-279.76%
84.60
+259.28%
-53.11
Issuance Of Debt
43.96
+4784.56%
0.90
-99.59%
219.92
0.00
Repayment Of Debt
-73.38
+52.03%
-152.97
-13.04%
-135.33
-154.79%
-53.11
Long Term Debt Issuance
43.96
+4784.56%
0.90
-99.59%
219.92
0.00
Long Term Debt Payments
-73.38
+52.03%
-152.97
-13.04%
-135.33
-154.79%
-53.11
Net Long Term Debt Issuance
-29.42
+80.66%
-152.07
-279.76%
84.60
+259.28%
-53.11
Net Common Stock Issuance
-1.55
0.00
0.00
-100.00%
0.35
Common Stock Payments
-1.55
0.00
0.00
—
Cash Dividends Paid
0.00
0.00
0.00
0.00
Repurchase Of Capital Stock
-1.55
0.00
0.00
—
Proceeds From Stock Option Exercised
0.23
-38.86%
0.37
+68.04%
0.22
-36.34%
0.34
Net Other Financing Charges
-1.46
+61.43%
-3.80
—
—
Changes In Cash
124.78
+158.20%
-214.39
-325.41%
95.11
+135.87%
-265.13
Effect Of Exchange Rate Changes
-12.65
-228.24%
9.87
+1431.99%
0.64
+103.38%
-19.04
Beginning Cash Position
306.39
-40.03%
510.91
+23.06%
415.15
-40.63%
699.33
End Cash Position
418.52
+36.60%
306.39
-40.03%
510.91
+23.06%
415.15
Free Cash Flow
-91.80
+19.48%
-114.02
+36.50%
-179.56
-834.18%
24.46
Change In Income Tax Payable
—
—
—
29.39
Change In Tax Payable
—
—
—
29.39
Common Stock Issuance
—
0.00
-100.00%
0.22
-38.31%
0.35
Dividends Received CFI
1.05
0.00
0.00
—
Earnings Losses From Equity Investments
1.08
-74.84%
4.31
-79.22%
20.75
+37.45%
15.10
Interest Paid CFF
-5.42
+8.36%
-5.92
+53.94%
-12.85
-124.27%
-5.73
Interest Paid CFO
—
—
—
-9.80
Interest Received CFI
4.11
-27.15%
5.65
-45.52%
10.37
+242.53%
3.03
Interest Received CFO
—
—
—
3.03
Issuance Of Capital Stock
—
0.00
-100.00%
0.22
-38.31%
0.35
Sale Of Business
230.83
+232.75%
69.37
+1891.10%
3.48
0.00
Taxes Refund Paid
14.78
-80.57%
76.08
+689.70%
-12.90
+30.26%
-18.50
SEC Filings

No SEC filings found for this symbol (may be non-US or ticker not in SEC index).

Trades
Date User Broker Pattern Type Position Size Entry Price Trade P&L Status
Posts
Published Title Author Category